Emixustat - Kubota Vision
Alternative Names: ACU-02; ACU-4429; ACU-4429 HCl; Emixustat HCl; Emixustat hydrochloride; RETAKULatest Information Update: 09 Dec 2024
At a glance
- Originator Acucela
- Developer Kubota Vision; Otsuka Pharmaceutical
- Class Cyclohexanes; Eye disorder therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Retinoid isomerohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Stargardt disease
- Phase II Diabetic retinopathy
- Discontinued Dry age-related macular degeneration
Most Recent Events
- 09 Dec 2024 Emixustat is still in phase III trials for Stargardt disease (In adolescents, In adults, In the elderly) in United Kingdom, Brazil, Denmark, Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA (PO) (NCT03772665)
- 23 Jun 2022 Kubota Vision completes the phase III SeaSTAR trial in Stargardt disease in US, Brazil, Canada, Denmark, France, Germany, Italy, the Netherlands, South Africa, Spain and the UK (PO) (NCT03772665) (EudraCT2018-003498-82)
- 09 Mar 2022 Emixustat is still in phase III trials for Stargardt disease (In adolescents, In adults, In the elderly) in United Kingdom, Brazil, Denmark, Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA (PO) (NCT03772665)